1. Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
   Henry G. Kaplan et al, 2022, Breast Cancer Research and Treatment CrossRef
2. A Case Report on Prolonged Response with Trastuzumab Emtansine (T-DM1) in Recurrent Advance Breast Cancer Setting
   Praneet Singh Bedi et al, 2023, Journal of Cancer Research Updates CrossRef